BACKGROUND: To provide rapid immunosuppression without side effects, we analyzed whether rapamycin alone, and regulatory T cells (Tregs) expanded ex vivo by rapamycin, suppressed colitis in a mouse model. METHODS: Severe combined immunodeficiency (SCID) mice reconstituted with naive CD4(+) T cells were treated with or without intraperitoneal rapamycin. Body weight was evaluated. CD4(+) T cells were cultured in the presence of rapamycin for three 7-day rounds of stimulation. The ratio of Tregs to CD4(+) T cells was analyzed by flow cytometry. Naive CD4(+) T cells were transferred into SCID mice with CD4(+) T cells expanded in the presence or absence of rapamycin. Clinical symptoms of colitis, histological changes, and cytokine expression were investigated. RESULTS: Systemic rapamycin partially prevented the development of colonic inflammation in a transfer model of colitis, but decreased body weight in control mice. With rapamycin, stimulated CD4(+) T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%. Without rapamycin, CD4(+) T cells expanded 20-fold in 3 weeks, but the proportion of Tregs remained at about 15%. CD4(+) T cells expanded with rapamycin prevented the development of colitis in a naïve CD4(+) T-cell transfer model, in association with the downregulation of Th1 and Th17 responses. CONCLUSIONS: We demonstrated, for the first time, that CD4(+) T cells expanded with rapamycin in vitro suppressed colitis. Therefore, rapamycin-expanded Treg transfer therapy is expected to be efficacious for inflammatory bowel disease.
BACKGROUND: To provide rapid immunosuppression without side effects, we analyzed whether rapamycin alone, and regulatory T cells (Tregs) expanded ex vivo by rapamycin, suppressed colitis in a mouse model. METHODS: Severe combined immunodeficiency (SCID) mice reconstituted with naive CD4(+) T cells were treated with or without intraperitoneal rapamycin. Body weight was evaluated. CD4(+) T cells were cultured in the presence of rapamycin for three 7-day rounds of stimulation. The ratio of Tregs to CD4(+) T cells was analyzed by flow cytometry. Naive CD4(+) T cells were transferred into SCIDmice with CD4(+) T cells expanded in the presence or absence of rapamycin. Clinical symptoms of colitis, histological changes, and cytokine expression were investigated. RESULTS: Systemic rapamycin partially prevented the development of colonic inflammation in a transfer model of colitis, but decreased body weight in control mice. With rapamycin, stimulated CD4(+) T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%. Without rapamycin, CD4(+) T cells expanded 20-fold in 3 weeks, but the proportion of Tregs remained at about 15%. CD4(+) T cells expanded with rapamycin prevented the development of colitis in a naïve CD4(+) T-cell transfer model, in association with the downregulation of Th1 and Th17 responses. CONCLUSIONS: We demonstrated, for the first time, that CD4(+) T cells expanded with rapamycin in vitro suppressed colitis. Therefore, rapamycin-expanded Treg transfer therapy is expected to be efficacious for inflammatory bowel disease.
Authors: Nathalie Holmén; Anna Lundgren; Samuel Lundin; Ann-Marie Bergin; Anna Rudin; Henrik Sjövall; Lena Ohman Journal: Inflamm Bowel Dis Date: 2006-06 Impact factor: 5.325
Authors: Lisa M Kosloski; Elizabeth A Kosmacek; Katherine E Olson; R Lee Mosley; Howard E Gendelman Journal: J Neuroimmunol Date: 2013-10-29 Impact factor: 3.478
Authors: Manuel Wiesinger; Diane Stoica; Susanne Roessner; Carmen Lorenz; Anika Fischer; Raja Atreya; Clemens F Neufert; Imke Atreya; Alexander Scheffold; Beatrice Schuler-Thurner; Markus F Neurath; Gerold Schuler; Caroline J Voskens Journal: Front Immunol Date: 2017-10-26 Impact factor: 7.561
Authors: Cameron S Field; Francesc Baixauli; Ryan L Kyle; Daniel J Puleston; Alanna M Cameron; David E Sanin; Keli L Hippen; Michael Loschi; Govindarajan Thangavelu; Mauro Corrado; Joy Edwards-Hicks; Katarzyna M Grzes; Edward J Pearce; Bruce R Blazar; Erika L Pearce Journal: Cell Metab Date: 2019-12-26 Impact factor: 27.287